Borray New Creation Biopharmaceutical Technology

Borray New Creation Biopharmaceutical Technology is a clinical-stage biotechnology company based in Suzhou, China, and a subsidiary of BrightGene Bio-Medical Technology. The company specializes in the development of innovative biopharmaceuticals, with a primary focus on long-acting injectable drugs and multi-target peptide therapies for metabolic diseases and oncology. Its lead candidate, BGM0504, is a dual GLP-1 and GIP receptor agonist currently in Phase 2 clinical trials for the treatment of obesity and type 2 diabetes. Borray New Creation leverages advanced drug delivery and formulation platforms to enhance the pharmacokinetic profiles of complex molecules. The company's pipeline also includes novel polymer-drug conjugates designed to improve the safety and efficacy of established chemotherapeutic agents.